With the outbreak of novel coronavirus COVID-19, it’s inevitable that there will be disruptions to supply chains.
Quarantines may slow or halt activities in manufacturing plants or they may impact transportation and ports. This is a global issue.
PHARMAC is working closely with the Ministry of Health’s National Health Coordination Centre (NHCC) in its response to the pandemic.
Last updated: 27 March 2020
Special Authority changes
We're changing criteria for some Special Authority applications to ease the burden on the health system.
More changes are approved for the following medicines:
- octreotide LAR
Details will be provided on Monday, 30 March 2020.
This is a rapidly evolving situation. PHARMAC is continuing to review Special Authorities and other processes to support the health sector and ensure people can continue to access funded medicines.
COVID-19 information for:
> Bosentan and Sildenafil - change to Special Authority (page added 27/3/2020)
> Dornase alfa - change to Special Authority (page added 27/3/2020)
> Entresto – Sacubitril with valsartan - change to Special Authority (page added 26/3/2020)
> Insulin pump consumables - change to Special Authority (page added 27/3/20)
> Pembrolizumab and nivolumab - Change to Special Authority (page added 27/3/20)
> PrEP (emtricitabine with tenofovir disoproxil) - Change to Special Authority (page added 26/3/20)